Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seagen Inc.; Seattle Genetics, Inc.
• Treatments: Antibodies; Antibodies, Monoclonal; Brentuximab Vedotin

Criteria

Inclusion Criteria:

• Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy

• Have failed, refused, or have been deemed ineligible for standard therapy

• Measurable disease

• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70

Exclusion Criteria:

• Primary diagnosis of lymphoma or central nervous system (CNS) malignancy

• History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years

• Evidence of active cerebral/meningeal disease